The two core skincare demands – pursuing skin brightening and combating pigmentation – essentially boil down to regulating melanin production. Beyond cosmetic concerns, this mechanism is also closely linked to the treatment of numerous dermatological disorders. Skin darkening stems from sophisticated biological processes; melanin does not form spontaneously but is tightly governed by multiple signaling pathways. Accordingly, optimal brightening outcomes cannot be achieved simply by blocking a single reaction step or one individual pathway. To fully grasp how melanogenesis is controlled, explore the following introduction on related signaling pathways.
A series of intricate enzymatic reactions for melanin synthesis take place inside melanosomes of melanocytes, which can be divided into two main phases. In the first stage, tyrosine is converted into DOPA under the catalysis of tyrosinase, followed by further oxidation to dopaquinone. Dopaquinone acts as a critical branching point for downstream synthetic routes. In the presence of cysteine or glutathione, dopaquinone reacts with these substances to eventually form yellowish-red pheomelanin. By contrast, without the two substances, dopaquinone undergoes spontaneous cyclization into dopachrome, which is then converted into 5,6-dihydroxyindole-2-carboxylic acid (DHICA) catalyzed by tyrosinase-related protein 2 (TRP-2). Finally, tyrosinase-related protein 1 (TRP-1) facilitates the production of eumelanin, the common brown-black skin pigment. It is therefore clear that tyrosinase serves as the core regulator governing the whole biosynthetic process.Then which factor dictates the activities of these enzymes and proteins? The answer is microphthalmia-associated transcription factor (MITF). Regarded as the master controller of melanogenesis, MITF binds to specific sequences within the promoter regions of TYR, TRP1 and TRP2 genes to trigger the expression of these key enzymes. Meanwhile, MITF activity is precisely modulated by five major signaling pathways, the core brightening-related pathways elaborated in this article.
The first pathway is the MC1R/α‑MSH signaling pathway, also known as the cAMP‑dependent pathway, the core route responsible for UVB‑triggered skin pigmentation. Upon UVB irradiation of the skin, keratinocytes secrete α‑melanocyte‑stimulating hormone (α‑MSH). This signaling molecule binds to the melanocortin 1 receptor (MC1R) located on the melanocyte membrane. The binding event activates the intracellular secondary messenger cyclic adenosine monophosphate (cAMP), which subsequently turns on protein kinase A (PKA). Activated PKA translocates into the nucleus to phosphorylate and activate transcription factor CREB, ultimately upregulating MITF expression and initiating the entire melanin biosynthesis cascade.
The second pathway is the PI3K/Akt signaling pathway. It can be activated by cAMP under certain conditions yet functions independently of PKA. Once activated, phosphatidylinositol 3‑kinase (PI3K) triggers the phosphorylation and activation of protein kinase B (Akt). Activated Akt further phosphorylates and inhibits glycogen synthase kinase‑3β (GSK3β). Reduced GSK3β activity enhances the DNA‑binding affinity of MITF, consequently boosting melanogenesis. Studies have confirmed that the inflammatory cytokine interleukin‑10 (IL‑10) upregulates melanin production via activating this pathway.
The third pathway is the MAPK signaling pathway, an intricate signaling network whose distinct branches may exert entirely opposite biological effects. For instance, stimulation by stem cell factor (SCF) or endothelin‑1 (EDN‑1) activates extracellular signal‑regulated kinase (ERK). Activated ERK accelerates MITF degradation and therefore suppresses melanogenesis. On the contrary, ERK activation can also phosphorylate CREB to upregulate MITF expression. In addition, phosphorylation of p38 within this pathway evidently activates MITF and promotes melanin synthesis. Although such sophisticated and seemingly contradictory regulatory modes appear complicated, they enable melanocytes to respond precisely to diverse environmental cues.
The fourth pathway is the Wnt/β‑catenin signaling pathway. Under resting conditions, β‑catenin is phosphorylated and degraded by GSK3β. Upon pathway activation, GSK3β is inhibited, resulting in cytoplasmic accumulation of β‑catenin, which subsequently translocates into the nucleus. Inside the nucleus, β‑catenin binds to corresponding transcription factors to synergistically boost MITF expression and further stimulate melanogenesis.
The fifth pathway is the NO signaling pathway. Produced in keratinocytes upon UV irradiation, nitric oxide (NO) diffuses into melanocytes as a signaling molecule and binds to its primary receptor soluble guanylate cyclase (sGC). This binding triggers the synthesis of another second messenger cGMP. Elevated cGMP levels activate protein kinase G (PKG), which further upregulates MITF expression and ultimately accelerates melanin synthesis.
Apart from inhibiting melanin biosynthesis, an alternative brightening strategy is to block melanin transfer. After being synthesized inside melanocytes, melanosomes have to be transported into surrounding keratinocytes to manifest skin pigmentation. Protease‑activated receptor 2 (PAR‑2) functions as a transporter during this delivery process. UV radiation upregulates PAR‑2 expression and enhances melanosome uptake by keratinocytes. Accordingly, suppressing PAR‑2 activity effectively hinders melanosome translocation, constituting a novel approach for skin brightening.
Evidently, skin pigmentation intensity is governed by an extraordinarily intricate signaling network. Every step from UV sensing and hormonal signal transduction to enzymatic modulation and melanosome trafficking contains potential intervention targets. In the past, brightening development was limited to direct tyrosinase inhibition; nowadays, research evolves toward more refined and fundamental regulation of signaling pathways. In-depth understanding of melanogenic signaling pathways facilitates the development of targeted brightening solutions acting on specific signaling nodes.
